Despite advancements in treatment, patients with Systemic Lupus Erythematosus (SLE) frequently experience disease flares, which contribute to organ damage and increase the risk of premature death. Assessing disease activity is essential for optimizing treatment and preventing further organ damage. This study aimed to investigate the relationship between levels of progenitor and circulating endothelial cells and SLE disease activity, as well as accumulated organ damage.
Methods
We conducted a case-control study measuring levels of CD34+CD45low/- progenitor cells, CD34+CD45low/-CD133+ progenitor cells, Endothelial Progenitor Cells (EPC), and Circulating Endothelial Cells (CEC) in peripheral blood using flow cytometry.
Results
The study included 32 SLE patients and 28 matched controls. SLE patients exhibited significantly lower levels of CD34+CD45low/- progenitor cells (p = .001), CD34+CD45low/-CD133+ progenitor cells (p = .016), EPC (p = .018), and CEC (p < .001) compared to controls. Additionally, the cell subpopulations correlated with SLE activity biomarkers, with CD34+CD45low/- progenitor cells showing a moderate negative correlation with C3 and C4 levels. Notably, patients with an SDI score ≥1 had significantly higher levels of CD34+CD45low/- progenitor cells, CD34+CD45low/- CD133+ progenitor cells, EPC, and CEC compared to those without organ damage (p = .0073, p = .018, p = .018, and p = .020, respectively).
Conclusion
Our findings reveal that CD34+CD45low/- progenitor cells, CD34+CD45low/-CD133+ progenitor cells, EPC, and CEC are significantly reduced in SLE patients and are associated with disease activity and organ damage. These results suggest that CD34+CD45low/- progenitor cells, in particular, could serve as potential biomarkers for monitoring disease activity and organ damage in SLE patients. Prospective studies are warranted to confirm these findings.
PellicciaFZimarinoMDe LucaG, et al.Endothelial progenitor cells in coronary artery disease: from bench to bedside. Stem Cells Transl Med2022; 11: 451–460.
7.
VinciMCCarulliERuraliE, et al.The long telling story of “endothelial progenitor cells”: where are we at now?Cells2023; 12: 112.
8.
MakAChanJKY. Endothelial function and endothelial progenitor cells in systemic lupus erythematosus. Nat Rev Rheumatol2022; 18: 286–300.
9.
DingXXiangWHeX. IFN-I mediates dysfunction of endothelial progenitor cells in atherosclerosis of systemic lupus erythematosus. Front Immunol2020; 11: 581385.
10.
InêsLSilvaCGalindoM, et al.Classification of systemic lupus erythematosus: systemic lupus international collaborating clinics versus American college of rheumatology criteria. A comparative study of 2,055 patients from a real-life, international systemic lupus erythematosus cohort. Arthritis Care Res2015; 67: 1180–1185.
11.
PetriMOrbaiAMAlarcõnGS, et al.Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum2012; 64: 2677–2686.
12.
YeeCSFarewellVTIsenbergDA, et al.The use of systemic lupus erythematosus disease activity index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology2011; 50: 982–988.
MokCC. Biomarkers for lupus nephritis: a critical appraisal. J Biomed Biotechnol2010; 2010: 638413.
15.
Gómez-PuertaJAPons-EstelGJQuintanaR, et al.A longitudinal multiethnic study of biomarkers in systemic lupus erythematosus: launching the GLADEL 2.0 study group. Lupus2021; 30: 630–640.
16.
LeePYLiYRichardsHB, et al.Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum2007; 56: 3759–3769.
17.
MoonenJRAJde LeeuwKvan SeijenXJGY, et al.Reduced number and impaired function of circulating progenitor cells in patients with systemic lupus erythematosus. Arthritis Res Ther2007; 9: R84.
18.
WesterweelPELuijtenRKMACHoeferIE, et al.Haematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus erythematosus. Ann Rheum Dis2007; 66: 865–870.
19.
EbnerPPicardFRichterJ, et al.Accumulation of VEGFR-2+/CD133+ cells and decreased number and impaired functionality of CD34+/VEGFR-2+ cells in patients with SLE. Rheumatology2010; 49: 63–72.
20.
BakerJFZhangLImadojemuS, et al.Circulating endothelial progenitor cells are reduced in SLE in the absence of coronary artery calcification. Rheumatol Int2012; 32: 997–1002.
21.
CastejonRJimenez-ortizCValero-gonzalezS, et al.Decreased circulating endothelial progenitor cells as an early risk factor of subclinical atherosclerosis in systemic lupus erythematosus. Rheumatology2014; 53: 631–638.
22.
HuangJKowNYLeeHY, et al.CD34+CD133+CD309+ circulating angiogenic cell level is reduced but positively related to hydroxychloroquine use in SLE patients-a case-control study and meta-regression analysis. Rheumatology2021; 60: 3936–3944.
23.
DennyMFThackerSMehtaH, et al.Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood2007; 110: 2907–2915.
24.
GrisarJSteinerCWBonelliM, et al.Systemic lupus erythematosus patients exhibit functional deficiencies of endothelial progenitor cells. Rheumatology2008; 47: 1476–1483.
25.
DengXLLiXXLiuXY, et al.Comparative study on circulating endothelial progenitor cells in systemic lupus erythematosus patients at active stage. Rheumatol Int2010; 30: 1429–1436.
26.
Rafael-VidalCMartínez-RamosSMalvar-FernándezB, et al.Novel endothelial progenitor cells populations as biomarkers of damage and remission in systemic lupus erythematosus. Arthritis Res Ther2024; 26: 170.
27.
CastejonRJimenez-OrtizCRosadoS, et al.Metabolic syndrome is associated with decreased circulating endothelial progenitor cells and increased arterial stiffness in systemic lupus erythematosus. Lupus2016; 25: 129–136.
28.
LópezPRodríguez-CarrioJMartínez-ZapicoA, et al.Low-density granulocytes and monocytes as biomarkers of cardiovascular risk in systemic lupus erythematosus. Rheumatology2020; 59: 1752–1764.
29.
CastejonRCastañedaASolletA, et al.Short-term atorvastatin therapy improves arterial stiffness of middle-aged systemic lupus erythematosus patients with pathological pulse wave velocity. Lupus2017; 26: 355–364.
30.
OliveiraACDArismendiMIMachadoLSG, et al.Ramipril improves endothelial function and increases the number of endothelial progenitor cells in patients with systemic lupus erythematosus. J Clin Rheumatol2022; 28: 349–353.
31.
MoonenJRAJde LeeuwKvan SeijenXJGY, et al.Reduced number and impaired function of circulating progenitor cells in patients with systemic lupus erythematosus. Arthritis Res Ther2007; 9: R84.
32.
DennyMFThackerSMehtaH, et al.Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood2007; 110: 2907–2915.
33.
BanchereauJPascualV. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity2006; 25: 383–392.
34.
SimTMOngSJMakA, et al.Type I interferons in systemic lupus erythematosus: a journey from bench to bedside. Int J Mol Sci2022; 23: 2505.
35.
DingXXiangWYiR, et al.Neutralizing interferon-α blocks inflammation-mediated vascular injury via PI3K and AMPK in systemic lupus erythematosus. Immunology2021; 164: 372–385.
36.
DennyMFYalavarthiSZhaoW, et al.A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol2010; 184: 3284–3297.
37.
BlannADWoywodtABertoliniF, et al.Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost2005; 93: 228–235.
38.
Kachamakova-TrojanowskaNBukowska-StrakovaKZukowskaM, et al.The real face of endothelial progenitor cells - circulating angiogenic cells as endothelial prognostic marker?Pharmacol Rep2015.
39.
HeinischPPBelloCEmmertMY, et al.Endothelial progenitor cells as biomarkers of cardiovascular pathologies: a narrative review. Cells2022; 11: 1678.
40.
PerdomoSBrugniniATriasN, et al.Mobilized and apheresis-collected endothelial progenitor cells with plerixafor. J Clin Apher2022; 37: 245–252.
41.
SpinelliFRBarbatiCCecarelliF, et al.B lymphocyte stimulator modulates number and function of endothelial progenitor cells in systemic lupus erythematosus. Arthritis Res Ther2019; 21: 245.
